Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 132, P. 102898 - 102898

Published: Aug. 24, 2022

Language: Английский

---

Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

International Journal of Environmental Research and Public Health, Journal Year: 2022, Volume and Issue: 19(16), P. 10228 - 10228

Published: Aug. 17, 2022

Increasing evidence relate anti-SARS-CoV-2 vaccinations to orofacial adverse reactions, therefore, the present systematic review aimed evaluate primary oral lesions diagnosed in adult subjects, following WHO Emergency Use Listing approved and EMA authorized vaccines, also relation cases' age, gender, comorbidities, history of COVID-19, vaccine type doses. The study protocol, registered on PROSPERO (CRD42022339032) compliant with PRISMA statement, included an electronic search across Scopus, MEDLINE/PubMed, BioMed Central databases, PROSPERO, ended 18 June 2022 succeeded by a manual search, independent data extraction, arisk bias evaluation through ROBINS-I tool. Qualitatively synthesized from 13studies showed overall low prevalence (16 cases), though higher females (68.8%), lesions, mainly erosions ulcers (34.5%). Nine cases were Pfizer-BioNTech, two Moderna, one AstraZeneca, Serum Institute India, Sinopharm, Johnson&Johnson respectively; specifically, eight after first dose seven second. In case, not specified. Considering newly developing presented findings may be updated further studies needed highlight factors affecting lesion occurrence specific macro-microscopic phenotypes vaccines' characteristics.

Language: Английский

---

Oral Lesions in Pediatric Subjects: SARS-CoV-2 Infection and COVID-19 Vaccination

Applied Sciences, Journal Year: 2022, Volume and Issue: 12(18), P. 8995 - 8995

Published: Sept. 7, 2022

A plethora of systemic manifestations COVID-19 and adverse reactions to vaccines have been described in pediatric subjects. Therefore, the present systematic review primarily aimed assess prevalence macro-microscopic features oral lesions following SARS-CoV-2 infection, grading primary based on forms, The secondary aim was evaluate epidemiology, clinical appearance, histopathology WHO Emergency Use Listing approved EMA authorized vaccines, relation cases vaccine characteristics. study protocol compliant with PRISMA statement registered PROSPERO (CRD42022351821). Case reports, case series, observational studies were electronically searched till 27 July 2022, MEDLINE/PubMed, Scopus, Cochrane library databases, register. Data from nine describing viral infection two records reporting administration, evaluated through ROBINS-I tool for quality, independently extracted qualitatively synthesized, resulting scarce, jeopardized, incomplete findings. Since most rare recorded a part broad-spectrum disorders syndromes and, thus. undetailed or nonspecific, further should vaccination subjects, considering novel variants newly developing vaccines.

Language: Английский

---

Five cases of new‐onset pemphigus following vaccinations against coronavirus disease 2019

The Journal of Dermatology, Journal Year: 2022, Volume and Issue: 50(2), P. 229 - 233

Published: Aug. 17, 2022

Abstract Pemphigus is a group of blistering disorders characterized by the formation intraepithelial blisters in skin and mucous membranes induced binding circulating autoantibodies to intercellular adhesion molecules. The pathogenesis complex not fully understood; however, genetic predisposition various triggers are widely accepted as key factors pemphigus development. A few cases new‐onset following coronavirus disease 2019 (COVID‐19) vaccination have already been published. present paper reports total two foliaceous three vulgaris that occurred vaccinations against COVID‐19, with anamnestic, clinical, diagnostic data collection suggesting assumptions over possible causal correlation.

Language: Английский

---

The multifactorial complexities of autoimmune development in Pemphigus vulgaris: Critical evaluation of the role of environmental and lifestyle “exposome” factors

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 10, 2023

Pemphigus vulgaris (PV) is a potentially life-threatening blistering disorder characterized by autoantibodies directed against cell-cell adhesion molecules that serves as an excellent model to study human autoimmune development. Numerous studies have identified specific Human Leukocyte Antigen (HLA) genes, in particular DRB1*0402 and DQB1*0503, confer disease risk. Although HLA required, it not sufficient for the initiation of disease. As with all diseases, etio-pathogenesis PV complex, meaning multifactorial. Susceptibility polygenic, search non-HLA disease-linked genes continues. Moreover, twin across conditions indicate non-genetic environmental lifestyle factors, which can be collectively grouped under term “exposome”, are also major contributors The literature presents evidence potential role multiple triggers such medications, infections, stress, diet, immunizations, sleep influence etiology, pathophysiology, prognosis PV. However, clear understanding degree factors impact lacking. In this investigation, we comprehensively review elements listed above consider strength these factors. overall goals work provide greater insights into susceptibility, development course ultimately help better guide clinicians inform patients management

Language: Английский

---

New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: April 8, 2024

Numerous cutaneous manifestations have been associated with the Coronavirus Disease 2019 (COVID-19) outbreak and vaccination, but new-onset bullous pemphigoid (BP) or flaring up of pre-existing BP is a rare side effect COVID-19 vaccines that has mentioned to lesser extent in literature. Therefore, we aimed conduct systematic review focused on association between new- onset flare-up vaccination.

Language: Английский

---

Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

We conducted a nationwide survey in Japan to clarify the clinical spectrum of these events. An initial questionnaire was sent 126 dermatology facilities, and responses were obtained from 66 (52.4%). Among responding most commonly identified cutaneous adverse events after COVID-19 vaccination urticaria (49 (74.2%)), delayed local reactions (37 (56.1%)), erythema multiforme (31 (47.0%)), alopecia (30 (45.5%)). The primary (19 (20.9%)), bullous pemphigoid (7 (7.7%)), (6 (6.6%)). mean latency onset 13.1 days, duration symptoms 74.2 days. Although this study cannot establish direct causal relationship between events, it highlights need for dermatologists recognize potential provide appropriate care.

Language: Английский

---

IgA pemphigus following SARS-Cov-2 vaccine

Italian Journal of Dermatology and Venereology, Journal Year: 2025, Volume and Issue: 160(2)

Published: April 1, 2025

Language: Английский

---

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: Jan. 19, 2023

Autoimmune bullous diseases (AIBDs) are a heterogeneous group of life-threatening disorders associated with subepidermal or intraepidermal blistering. Skin barrier alterations and prolonged immunosuppressive treatments increase the risk infections in patients AIBDs, who considered fragile. COVID-19 pandemic had heavy impact on these patients. Although advances have been made terms prevention treatment COVID-19, this topic remains significant as its waves could last several years and, so far, relevant proportion population worldwide is not vaccinated. This review 2022 update that summarizes discusses pandemic's burden AIBD mainly considering studies of: (i) sample dimension; (ii) quality control populations; (iii) possible standardization by age, gender country. The findings show that: infection severe course were comparable general population, except for rituximab-treated presented higher disease; mortality rate COVID-19-infected pemphigoid was than 121 cases onset 185 relapse exacerbation occurred after vaccination causal relationship has demonstrated far. Altogether, acquired knowledge also be important possible, albeit undesirable, future scenarios.

Language: Английский

---

IgA pemphigus following COVID-19 vaccination: A case report

SAGE Open Medical Case Reports, Journal Year: 2023, Volume and Issue: 11

Published: Jan. 1, 2023

A patient presented with pruritic lesions on their back and leg after COVID-19 vaccination. Biopsy direct immunofluorescence were consistent IgA pemphigus—likely caused by the vaccine.

Language: Английский

---